Core Insights - Onco3R Therapeutics is presenting preclinical data on its FGFR3, SMARCA2, and P53 Y220C small molecule programs at the EORTC-NCI-AACR Symposium, highlighting advancements in oncology drug development [1][5]. Company Overview - Onco3R Therapeutics focuses on developing best-in-class medicines to address unmet needs in oncology and autoimmune diseases, leveraging over 150 years of combined R&D experience [7]. - The company aims to transform patient lives through precision-designed therapies, integrating advanced technologies and learnings from past clinical challenges [7]. Drug Development Highlights - The FGFR3 candidate G-012 has demonstrated best-in-class potency and selectivity, showing robust anti-proliferative activity in FGFR3-driven cancer cells and significant tumor regression in vivo [6][10]. - The SMARCA2 candidate G-141 exhibits optimal target coverage and has shown synthetic lethality in SMARCA4-deficient cells, with favorable drug-like properties [10]. - The P53 Y220C reactivator candidates have shown robust anti-proliferative activity in P53 Y220C mutant cancer cell lines, indicating potential for significant therapeutic impact [11]. Future Plans - Onco3R anticipates initiating IND-enabling studies for its FGFR3 and SMARCA2 candidates in mid-2026, reinforcing its strategic position in the biotech industry [3][5].